Literature DB >> 8901377

The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires.

D Osoba1, N K Aaronson, M Muller, K Sneeuw, M A Hsu, W K Yung, M Brada, E Newlands.   

Abstract

A self-report questionnaire module consisting of 24 items, comprising 5 scales and 7 single items, has been developed for measuring health-related quality of life in patients with brain cancer. Module development proceeded through several stages, including a listing of patient, family and health care professional concerns, the writing of items, field testing in 105 patients with brain cancer and subsequent item reduction and scale construction after multitrait scaling analysis and assessment of internal consistency (Cronbach's coefficient alpha). The final version of the module exhibits reasonable test-retest stability over a period of one week. Differences in the responses between patients with recently-diagnosed and recurrent cancer and between patients with a Karnofsky Performance Score (KPS) of 50-70 and 80-100 were in the expected direction, indicating that the module of questions is responsive to differing conditions. Patients with either mental confusion, motor deficit or dysphasia indicated problems in several domains and single items as compared to patients without these neurological deficits. Thus, differences in the responses to the items in the brain cancer module appear to reflect differences in neurological status. In addition, deteriorating neurological status was accompanied by a marked increase in emotional distress, future uncertainty and motor dysfunction. A comparison of the responses in the module with the KPS and with a modified Barthel Activities of Daily Living Index (BADLI) shows moderate correlations, primarily with scales and items that pertain to motor dysfunction, while other scales (such as emotional distress, visual disorder and communication deficit) and most single items are not associated with the KPS or BADLI. Since the emotional distress scale of the module was found to be highly correlated with the emotional function scale of the EORTC QLQ-C30, it could be omitted when the module is used in combination with the QLQ-C30. This would reduce the module to a total of 20 items with four scales and seven single items. The intention is to combine this module of questions with other core or general quality-of-life questionnaires when studying patients with brain cancer in clinical trials.

Entities:  

Mesh:

Year:  1996        PMID: 8901377     DOI: 10.1007/bf00435979

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  10 in total

1.  Assessment of quality of life in patients treated for low-grade glioma: a preliminary report.

Authors:  M J Taphoorn; J J Heimans; F J Snoek; J Lindeboom; B Oosterink; J G Wolbers; A B Karim
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-05       Impact factor: 10.154

2.  Self-rating symptom checklists: a simple method for recording and evaluating symptom control in oncology.

Authors:  D Osoba
Journal:  Cancer Treat Rev       Date:  1993       Impact factor: 12.111

3.  A modular approach to quality-of-life assessment in cancer clinical trials.

Authors:  N K Aaronson; M Bullinger; S Ahmedzai
Journal:  Recent Results Cancer Res       Date:  1988

4.  Quality of life in patients with intracranial tumors on the basis of Karnofsky's performance status.

Authors:  W Sachsenheimer; W Piotrowski; T Bimmler
Journal:  J Neurooncol       Date:  1992-06       Impact factor: 4.130

5.  The European Organization for Research and Treatment of Cancer. Approach to quality of life assessment: guidelines for developing questionnaire modules. EORTC Study Group on Quality of Life.

Authors:  M A Sprangers; A Cull; K Bjordal; M Groenvold; N K Aaronson
Journal:  Qual Life Res       Date:  1993-08       Impact factor: 4.147

6.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.

Authors:  N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes
Journal:  J Natl Cancer Inst       Date:  1993-03-03       Impact factor: 13.506

7.  Quality of life self-reports from 200 brain tumor patients: comparisons with Karnofsky performance scores.

Authors:  N Mackworth; P Fobair; M D Prados
Journal:  J Neurooncol       Date:  1992-11       Impact factor: 4.130

8.  The Quality of Life Committee of the Clinical Trials Group of the National Cancer Institute of Canada: organization and functions.

Authors:  D Osoba
Journal:  Qual Life Res       Date:  1992-06       Impact factor: 4.147

9.  Cognitive functioning in long-term survivors of high-grade glioma.

Authors:  Y M Archibald; D Lunn; L A Ruttan; D R Macdonald; R F Del Maestro; H W Barr; J H Pexman; B J Fisher; L E Gaspar; J G Cairncross
Journal:  J Neurosurg       Date:  1994-02       Impact factor: 5.115

10.  Recording neurological impairment in clinical trials of glioma.

Authors:  R Grant; J Slattery; A Gregor; I R Whittle
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

  10 in total
  114 in total

1.  Quality of life in patients with stable disease after surgery, radiotherapy, and chemotherapy for malignant brain tumour.

Authors:  A R Giovagnoli
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-09       Impact factor: 10.154

2.  Health-related quality of life in high-grade glioma patients.

Authors:  Bertrand C Liang
Journal:  Curr Neurol Neurosci Rep       Date:  2002-05       Impact factor: 5.081

3.  The patients' view: impact of the extent of resection, intraoperative imaging, and awake surgery on health-related quality of life in high-grade glioma patients-results of a multicenter cross-sectional study.

Authors:  Katrin Nickel; Mirjam Renovanz; Jochem König; Linda Stöckelmaier; Anne-Katrin Hickmann; Minou Nadji-Ohl; Jens Engelke; Elke Weimann; Dirk Freudenstein; Oliver Ganslandt; Lars Bullinger; Christian Rainer Wirtz; Jan Coburger
Journal:  Neurosurg Rev       Date:  2017-03-06       Impact factor: 3.042

4.  Effect of neurological dysfunction on health-related quality of life in patients with high-grade glioma.

Authors:  D Osoba; N K Aaronson; M Muller; K Sneeuw; M A Hsu; W K Yung; M Brada; E Newlands
Journal:  J Neurooncol       Date:  1997-09       Impact factor: 4.130

5.  The Brain Symptom and Impact Questionnaire in brain metastases patients: a prospective long-term follow-up study.

Authors:  Natalie Pulenzas; Saurabh Ray; Liying Zhang; Rachel McDonald; David Cella; Leigha Rowbottom; Arjun Sahgal; Hany Soliman; May Tsao; Cyril Danjoux; Breanne Lechner; Edward Chow
Journal:  CNS Oncol       Date:  2015-12-18

6.  Neurocognitive functioning and health-related quality of life in patients treated with stereotactic radiotherapy for brain metastases: a prospective study.

Authors:  Esther J J Habets; Linda Dirven; Ruud G Wiggenraad; Antoinette Verbeek-de Kanter; Geert J Lycklama À Nijeholt; Hanneke Zwinkels; Martin Klein; Martin J B Taphoorn
Journal:  Neuro Oncol       Date:  2015-09-18       Impact factor: 12.300

7.  Validation study of the Japanese version of MD Anderson Symptom Inventory for Brain Tumor module.

Authors:  Shota Tanaka; Iori Sato; Masamichi Takahashi; Terri S Armstrong; Charles S Cleeland; Tito R Mendoza; Akitake Mukasa; Shunsaku Takayanagi; Yoshitaka Narita; Kiyoko Kamibeppu; Nobuhito Saito
Journal:  Jpn J Clin Oncol       Date:  2020-07-09       Impact factor: 3.019

8.  Pitfalls in the assessment of disability in individuals with low-grade gliomas.

Authors:  Anneli Påhlson; Lena Ek; Gerd Ahlström; Anja Smits
Journal:  J Neurooncol       Date:  2003-11       Impact factor: 4.130

9.  A randomized trial of bevacizumab for newly diagnosed glioblastoma.

Authors:  Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

10.  Quality of life in brain tumor patients: the relative contributions of depression, fatigue, emotional distress, and existential issues.

Authors:  Guy Pelletier; Marja J Verhoef; Nasreen Khatri; Neil Hagen
Journal:  J Neurooncol       Date:  2002-03       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.